Celldex Therapeutics (NASDAQ:CLDX) : On Wednesday, The money flowed into the Celldex Therapeutics (NASDAQ:CLDX) stock with an uptick to downtick ratio was recorded at 1.78. Transactions worth $0.93 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.52 million. The total money flow into the stock was $0.41 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.29 million of block transactions on upticks. The total money flow in block trades was $0.29 million. In terms of price action, Celldex Therapeutics (NASDAQ:CLDX) traded down $0.05 during the session at $4.3. Compared to the previous days closing, the stock was down only by -1.15%. For the week, the stock is -1.38%, over previous weeks closing.
In an insider trading activity,The officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., Catlin Avery W sold 25,000 shares at $18 on November 23, 2015. The Insider selling transaction had a total value worth of $450,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 4.2% of Celldex Therapeutics shares according to the proxy statements. Institutional Investors own 85.71% of Celldex Therapeutics shares.
The company shares have dropped -82.63% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $28.08 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $4.24 and the 200 Day Moving Average price is recorded at $6.78. Celldex Therapeutics (NASDAQ:CLDX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.44 and $4.23 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.44. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.42, notching a gain of 1.61% for the day. The total traded volume was 2,379,425 . The stock had closed at $4.35 on the previous day.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.